In this written ‘Ask the Experts’ column, we bring together leaders from our partnered organizations (Alzheimer’s Research UK, Alzheimer’s Society and the UK DRI) to discuss what the future of dementia research might hold.
A blood test to diagnose individuals at risk of developing Alzheimer’s disease before symptoms arise may be closer to reality, as researchers report a 94% accuracy in recent findings.
Researchers have discovered small molecules in sebum responsible for a unique odor in people with Parkinson’s that could be used for early diagnosis.
A new study has suggested that monitoring levels of disease-specific microRNAs may be utilized as a potential biomarker for Huntington’s disease, potentially allowing early diagnosis.
A novel mouse model suggests brain ‘aging surge’ could be a key diagnosis period for Alzheimer’s disease, and provide new treatment possibilities.
Using FTIR spectroscopy and chemometirc techniques, researchers were able to successfully diagnose and differentiate between various neurodegenerative diseases including Alzheimer’s disease.
Researchers have suggested that neuropsychological tests can detect preclinical Alzheimer’s disease in cognitively intact older adults.
Defects in a gene associated with dopamine production have been linked to the early onset of Parkinson’s disease in Caucasians, with particular effect in adults under 50 years.
This study aimed to determine whether circular RNA (circRNA) molecules in peripheral blood mononuclear cells (PBMCs) could be used as novel non-invasive biomarkers for major depressive disorder (MDD).
MAGNIMS research providing revised criteria for clinicians using MRI for MS diagnostics has been presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) congress.
